{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:49:00Z","timestamp":1794948540248,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dutch Arthritis Society DAS"},{"name":"Innovative Medicines Initiative 2 Joint Undertaking Immune-Image","award":["831514"],"award-info":[{"award-number":["831514"]}],"id":[{"id":"https:\/\/ror.org\/019af4n30","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare clinical characteristics, imaging findings and treatment requirements of patients with immune checkpoint inhibitor-mediated polymyalgia rheumatica (ICI-PMR) and primary PMR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single centre, retrospective cohort study compared ICI-PMR in patients with cancer (n\u2009=\u200915) to patients with primary PMR (n\u2009=\u200937). A comparison was made between clinical symptoms, laboratory markers, ultrasonography, 18F-FDG-PET\/CT findings and treatment requirements related to PMR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with ICI-PMR less frequently fulfilled the EULAR\/ACR classification criteria for PMR (66.7%) than patients with primary PMR (97.3%). Morning stiffness, weight loss and elevation of the ESR were less frequently seen in patients with ICI-PMR. No differences were observed regarding the presence of inflammatory lesions on ultrasound of the shoulders and hips between the two groups. The Leuven and the Leuven\/Groningen 18F-FDG-PET\/CT scores were significantly lower in the ICI-PMR group. Finally, the ICI-PMR group could be managed with lower glucocorticoid doses than the primary PMR group, while this treatment could be discontinued more quickly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that ICI-PMR may have a milder course with less intense inflammation than primary PMR. ICI-PMR can be managed with a relatively low glucocorticoid dose. Our study underscores that ICI-PMR should be regarded as a PMR-like syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae099","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T01:24:37Z","timestamp":1707182677000},"page":"771-779","source":"Crossref","is-referenced-by-count":35,"title":["Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6407-2201","authenticated-orcid":false,"given":"Olof C B","family":"Vermeulen","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-4423","authenticated-orcid":false,"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5565-1164","authenticated-orcid":false,"given":"Riemer H J A","family":"Slart","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]},{"name":"Faculty of Science and Technology, Department of Biomedical Photonic Imaging, University of Twente , Enschede,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sandovici","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-6890","authenticated-orcid":false,"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T Jeroen","family":"Hilterman","sequence":"additional","affiliation":[{"name":"Pulmonology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Hiddinga","sequence":"additional","affiliation":[{"name":"Pulmonology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoukje F","family":"Oosting","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-9050","authenticated-orcid":false,"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert H","family":"de Heij","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan G","family":"Knapen","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A P","family":"Hospers","sequence":"additional","affiliation":[{"name":"Medical Oncology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2798-6765","authenticated-orcid":false,"given":"Kornelis S M","family":"van der Geest","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen , Groningen,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"2025032905210561300_keae099-B1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (New York, N.Y.)"},{"key":"2025032905210561300_keae099-B2","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"2025032905210561300_keae099-B3","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20;44","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"2025032905210561300_keae099-B4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014Clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B5","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/rheumatology\/keab483","article-title":"Comparison and validation of FDG-PET\/CT scores for polymyalgia rheumatica","volume":"61","author":"Van Der Geest","year":"2022","journal-title":"Rheumatology"},{"key":"2025032905210561300_keae099-B6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","article-title":"Pathogenesis, diagnosis and management of polymyalgia rheumatica","volume":"36","author":"Camellino","year":"2019","journal-title":"Drugs Aging"},{"key":"2025032905210561300_keae099-B7","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B8","doi-asserted-by":"crossref","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"2025032905210561300_keae099-B9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B10","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica\u2013like syndrome after immune checkpoint inhibitor therapy","volume":"81","author":"Martin De Fremont","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B11","doi-asserted-by":"crossref","first-page":"E210","DOI":"10.1136\/annrheumdis-2020-217381","article-title":"Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"van der Geest","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B12","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1136\/annrheumdis-2020-218276","article-title":"Management of immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"Van Der Geest","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B14","first-page":"672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study","volume-title":"Ann Intern Med","author":"Chuang","year":"1982"},{"key":"2025032905210561300_keae099-B15","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/rheumatology\/kex376","article-title":"Use of 18f-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica\u2013a prospective study of 99 patients","volume":"57","author":"Henckaerts","year":"2018","journal-title":"Rheumatology"},{"key":"2025032905210561300_keae099-B16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025032905210561300_keae099-B17","first-page":"e143","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume-title":"Lancet Oncol","author":"Seymour","year":"2017"},{"key":"2025032905210561300_keae099-B18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep395","article-title":"Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study","volume":"49","author":"Mackie","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2025032905210561300_keae099-B20","doi-asserted-by":"crossref","first-page":"943574","DOI":"10.3389\/fimmu.2022.943574","article-title":"Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica","volume":"13","author":"Reitsema","year":"2022","journal-title":"Front Immunol"},{"key":"2025032905210561300_keae099-B21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/ard-2022-222873","article-title":"Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica","volume":"82","author":"Jiemy","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025032905210561300_keae099-B22","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol Immunother"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/771\/57008179\/keae099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae099\/57008179\/keae099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/2\/771\/57008179\/keae099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T23:27:53Z","timestamp":1743377273000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/2\/771\/7604533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,9]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae099","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,2,9]]}}}